Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab
Journal of Viral Hepatitis · 2025
DOI: 10.1111/jvh.70005 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Dionysios Kogias und 11 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece. Hauptthemen laut MEDLINE: Hepatitis E, Rituximab, Immunocompromised Host, Antibodies, Monoclonal, Murine-Derived. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hepatitis E virus (HEV) infection is a frequent cause of acute viral hepatitis. Immunocompromised patients, especially those under anti‐CD20 regimens, are prone to chronic or treatment‐resistant courses of hepatitis E. We report a case of chronic HEV infection in a 36‐year‐old man with a history of thrombotic thrombocytopenic purpura treated with rituximab 6 months ago, who presented with new‐onset painless jaundice and malaise. Laboratory tests and imaging revealed signs of inflammation and hepatic dysfunction. Due to initial suspicion of autoimmune hepatitis, corticosteroid therapy was started. However, liver biopsy and positive HEV RNA value redefined the diagnosis. Serology tests revealed initially acute infection, which later progressed to chronic hepatitis E infection. Treatment with ribavirin, along with supportive care, achieved significant clinical and laboratory improvement, resolving jaundice, restoring normal transaminase and suppressing HEV RNA values. Further review of the literature highlights the impact of immunosuppression caused by anti‐CD20 therapies on HEV infection, as well as the challenges in both treatment and achieving sustained virus clearance in such patients. Moreover, this report underlines the importance of HEV screening in patients with hepatitis who have undergone anti‐CD20 therapies, shedding light on a situation that is not well described in the literature and should not be overlooked, even in developed countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
- Department of Microbiology, Democritus University of Thrace, Alexandroupolis, Greece.
- Department of Hemopathology, Evangelismos General Hospital, Athens, Greece.
ORCID-Profile: Dionysios Kogias
Zitieren
APA
Kogias, D., Gavriilidis, E., Antoniadou, C., Skeva, A., Kafalis, N., Tsilingiris, D., Kanellis, G., Panopoulou, M., Mitroulis, I., Ritis, K., Skendros, P., & Kouklakis, G. (2025). Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70005
Vancouver
Kogias D, Gavriilidis E, Antoniadou C, Skeva A, Kafalis N, Tsilingiris D, et al. Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70005
BibTeX
@article{Kogias2025,
author = {Kogias, Dionysios and Gavriilidis, Efstratios and Antoniadou, Christina and Skeva, Aikaterini and Kafalis, Nikolaos and Tsilingiris, Dimitrios and Kanellis, George and Panopoulou, Maria and Mitroulis, Ioannis and Ritis, Konstantinos and Skendros, Panagiotis and Kouklakis, Georgios},
title = {Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab},
journal = {Journal of Viral Hepatitis},
year = {2025},
doi = {10.1111/jvh.70005}
}
EUVIMED